Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Enanta Pharmaceuticals (ENTA) Receivables Refunds (2020 - 2025)

Enanta Pharmaceuticals' Receivables Refunds history spans 6 years, with the latest figure at $24000.0 for Q2 2025.

  • For Q2 2025, Receivables Refunds fell 99.93% year-over-year to $24000.0; the TTM value through Jun 2025 reached $24000.0, down 99.93%, while the annual FY2024 figure was $32.0 million, 3.21% up from the prior year.
  • Receivables Refunds reached $24000.0 in Q2 2025 per ENTA's latest filing, down from $33.8 million in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $37.3 million in Q3 2021 to a low of $24000.0 in Q2 2025.
  • Average Receivables Refunds over 5 years is $28.9 million, with a median of $30.6 million recorded in 2021.
  • Peak YoY movement for Receivables Refunds: skyrocketed 185.68% in 2021, then plummeted 99.93% in 2025.
  • A 5-year view of Receivables Refunds shows it stood at $28.8 million in 2021, then dropped by 0.17% to $28.7 million in 2022, then increased by 10.56% to $31.7 million in 2023, then increased by 2.24% to $32.4 million in 2024, then plummeted by 99.93% to $24000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Receivables Refunds are $24000.0 (Q2 2025), $33.8 million (Q1 2025), and $32.4 million (Q4 2024).